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Abstract Exposure of mesangial cells to superoxide, generated
by the hypoxanthine/xanthine oxidase system or by the redox
cycler 2,3-dimethoxy-1,4-naphthoquinone caused a concentra-
tion-dependent amplification of interleukin (IL)-1L-stimulated
nitrite production. The effect of superoxide was accompanied by
an increase in inducible nitric oxide synthase (iNOS) protein and
iNOS mRNA levels. Incubation of mesangial cells with super-
oxide alone did not induce iNOS expression. To elucidate
whether the increase of iNOS expression is due to transcriptional
upregulation we fused a 4.5-kb genomic iNOS fragment that
contains the transcriptional start site of the rat iNOS gene to a
luciferase reporter gene. In transient transfection studies, super-
oxide caused a 10-fold augmentation of iNOS promoter activity
in IL-1L-challenged mesangial cells. Our data identify super-
oxide as a co-stimulatory factor amplifying cytokine-induced
iNOS gene expression and subsequent nitric oxide (NO)
synthesis.
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1. Introduction
Glomerular mesangial cells (MC) are smooth muscle-like
pericytes that participate in the regulation of the glomerular
¢ltration rate [1]. Due to their ability to produce in£ammatory
mediators such as cytokines [2], chemokines [3], nitric oxide
(NO) [4], reactive oxygen species (ROS) [5] and products of
arachidonic acid metabolism [6], MC are thought to play an
important role during in£ammatory glomerular diseases [7].
Interleukin-1L (IL-1L) leads to the transcription of the in-
ducible form of NO-synthases (iNOS) in MC that results in
enhanced formation of cGMP and subsequent inhibition of
contractile responsiveness of MC [8]. The fact that the NOS-
inhibitor L-NMMA reduces severity in a rat model of glomer-
ular injury induced by anti-thymocyte serum suggests addi-
tional cytotoxic e¡ects of NO [9,10]. We have recently re-
ported that high amounts of exogenously delivered or
endogenously produced NO leads to apoptosis of MC
[11,12]. ROS are intermediates produced by in¢ltrating neu-
trophils and macrophages during in£ammation. Radeke et al.
[5] have shown that the superoxide radical (O32 ) the primary
product of ROS is also synthesized in human MC in response
to IL-1 or TNF-K. Whereas the iNOS is the only enzyme
responsible for high NO build-up in MC, the ROS system is
more complex. This is due to the existence of several O32
synthesizing enzymes that use di¡erent substrates including
NADPH oxidase, xanthine oxidase and cyclooxygenases.
Moreover, other enzymes like superoxide dismutase, catalase,
myeloperoxidase or non-enzymatic processes such as the Hab-
er-Weiss reaction produce O32 -derived ROS including hydro-
gen peroxide, hydroxyl radicals and hypohalous acids that
exert diverse biological e¡ects [13] including regulation of
gene transcription [14]. Sandau et al. [15] reported that NO
and O32 both are able to trigger apoptosis in rat MC. The
e¡ect was crucially determined by the ratio of NO and O32
indicating that both autacoids neutralize each other forming
peroxynitrite which is ine¡ective in this regard.
We have been interested in the complex regulation of iNOS
gene expression in MC [16^19] and have reported positive
feedback regulation of iNOS expression by its product NO
[20]. In this study we addressed the possible participation of
ROS and in particular O32 in iNOS expression in MC.
2. Materials and methods
2.1. Reagents
Human recombinant IL-1L was kindly provided by Dr. Ch. Ror-
dorf (Novartis, Pharma, Basel, Switzerland). A cDNA clone repre-
senting the murine inducible NO-synthase (pMac-NOS) was gener-
ously provided by Dr. J. Cunningham (Boston, MA, USA). Clone
pEX6 that represents human L-actin cDNA was a gift from Dr. U.
Aebi (Basel, Switzerland). [K-32P]dATP and ‘ready prime’ DNA label-
ling kit were obtained from Amersham Buchler (Braunschweig, Ger-
many). Nylon blotting membranes from Life Science (Schlei-
cherpSchuº ll, Dassel, Germany) or Millipore (Eschborn, Germany).
Tissue culture plastic was from Falcon (Becton-Dickinson, Heidel-
berg, Germany), media and sera from Gibco-BRL (Eggenstein,
Germany). Xanthine oxidase was purchased from Boehringer Mann-
heim (Mannheim, Germany). 2,3-Dimethoxy-1,4-naphthoquinone
(DMNQ) was from Calbiochem-Novabiochem (Bad Soden, Ger-
many). All other chemicals were purchased from Sigma (Deisenhofen,
Germany).
2.2. Cell culture
Rat glomerular MC were cultured as decribed previously [21]. MC
were grown in RPMI 1640 supplemented with 10% heat-inactivated
fetal calf serum (FCS), 2 mM glutamate, 5 ng/ml insulin, 100 U/ml
penicillin and 1 Wg/ml streptomycin. To obtain quiescent cells, MC
were maintained in serum-free Dulbecco’s minimal essential medium
(DMEM) supplemented with 0.1 mg/ml of fatty acid-free bovine se-
rum albumin for 24 h before cytokine treatment. MC were used be-
tween passages 8 and 19.
2.3. Nitrite analysis
Nitrite (NO32 ), the stable end-product of NO, was measured in the
culture medium with the Griess method using a ready to use reagent
(Merck, Darmstadt, Germany) as described [22].
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2.4. Northern blot analysis
Isolation of total cellular RNA from MC and Northern blotting
was performed as described previously [18,23]. Filter-bound RNA was
hybridized to the radiolabelled SmaI fragment of the murine cDNA
clone pMac-NOS. Equivalent loading of the RNA probes was cor-
rected after rehybridization of the ¢lter with a cDNA probe for L-ac-
tin (pEX6).
2.5. Generation of the anti-iNOS N-terminal antibody
A cDNA-fragment that represents 196 amino acids of the iNOS N-
terminus was cloned into the expression vector pDS56 and expressed
in E. coli strain M15. The His6-tagged polypeptide was puri¢ed using
the XPress-kit (Invitrogen, Groningen, Netherlands). Female New
Zealand rabbits were immunized and the antisera were tested in West-
ern blots. A prominent iNOS band at the expected size of 130 kDa
was obtained when protein was prepared from MC treated with IL-1L
[24].
2.6. Western blot analysis
MC grown in 10-cm dishes were lysed in homogenization bu¡er (20
mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2 mM dithiothreitol, 50 Wg/ml leupeptin, 1 mM phenylmethylsul-
fonyl £uoride (PMSF) and left on ice for 15 min. Extracts were so-
nicated three times for 10 s and centrifuged at 13 000 rpm for 2 min.
The protein concentration of the lysate was determined from the
supernatant by use of the Bradford protein assay (Bio-Rad, Mu«nchen,
Germany). 100 Wg of total protein from each sample was subjected to
SDS-PAGE (8% (w/v) acrylamide gel). Subsequently, the protein was
blotted to a nylon membrane and immunoreactive protein was de-
tected with the anti-iNOS N-terminal antibody.
2.7. Cloning of iNOS promoter region
A Lambda Dash library (Stratagene, Amsterdam, Netherlands) that
contains genomic rat DNA fragments partially digested with Sau3A
was screened for iNOS positive clones with a radiolabelled DNA-
fragment that represents a 1.1-kb promoter-distal HincII/Xba frag-
ment of the recently cloned iNOS-promoter [19,25]. One positive
clone that contains about 16 kb rat genomic DNA further referred
to as ViNOS2-1 was characterized by restriction analysis. Southern
blot analysis showed identical restriction patterns of ViNOS2-1 and
rat genomic DNA as long restriction sites represented in ViNOS2-1
were used indicating that ViNOS represents a continuous genomic
DNA. A PstI/PstI fragment that contains the iNOS 5P-£anking region
from 349 to about 36000 was cloned into the vector Bluescript KS
(Stratagene) further referred to as pBSPP3.
2.8. Construction of reporter gene fusions and luciferase reporter
gene assay
pGL3/2 was obtained by cloning a 1846-bp HincII/HincII fragment
[25] into the SmaI site of Bluescript KS. A fusion of the iNOS
promoter to the luciferase gene was generated by cloning a HindIII/
SstI fragment to the respective sites in the polylinker of the vector
pGL3 basic (Promega, Mannheim, Germany). pGL3/4 was con-
structed by exchanging a 1.8-kb KpnI/PstI fragment from pGL3/2
with a 4.5-kb KpnI/PstI fragment from pBSPP3. Correct cloning of
all constructs used was veri¢ed by sequence analysis using the auto-
mated sequence analyzer A310 (Perkin Elmer Applied Biosystems,
Weiterstadt, Germany). Transfection of MC with pGL3/2, pGL3/4
and plasmid pRL-CMV used as a control was performed with the
superfect reagent (Qiagen, Hilden, Germany). Luciferase activity
was measured using the dual reporter gene system (Promega).
2.9. Statistics
Statistical analysis was performed by Student’s t-test. P values
6 0.05 were considered as statistically signi¢cant.
3. Results
To evaluate e¡ects of O32 on IL-1L-induced iNOS transcrip-
tion in MC we used two O32 generating systems. One of
them is xanthine oxidase in combination with its substrate
hypoxanthine further referred to as HXXO [26]. More re-
cently another O32 generating reagent, the redox cycler
DMNQ has been used as a O32 donor for cell culture experi-
ments [27].
HXXO caused a concentration (2^32 mU) dependent po-
tentiation of NO32 levels in IL-1L-activated MC measured
after 24 h coincubation with a maximum of 5.5-fold (IL-1L
plus HXXO vs. IL-1L alone, Fig. 1A). In a similar manner but
to a lesser extent (up to 2.3-fold), DMNQ increased NO32
levels in MC coincubated with IL-1L (Fig. 1B). This e¡ect
was signi¢cant at concentrations higher than 1 WM. Both
O32 generators showed no signi¢cant e¡ect on NO
3
2 produc-
tion when applied without IL-1L (data not shown). As shown
by immunoblot analyses production of NO32 is paralleled by a
corresponding ampli¢cation of iNOS protein levels in MC
challenged with IL-1L and HXXO (Fig. 2A) or DMNQ
(Fig. 2B).
The molecular basis for NO production in response to cy-
tokines, cAMP or lipopolysaccharide is formed by a transcrip-
tional upregulation of iNOS gene expression in MC. [16,17].
Therefore we examined the in£uence of the O32 donors
HXXO and DMNQ on IL-1L-induced iNOS-mRNA steady-
state levels. HXXO and DMNQ augmented IL-1L-induced
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Fig. 1. E¡ects of HXXO and DMNQ on cytokine induced NO32
production. Quiescent MC were treated with vehicle (control), IL-1L
(1 nM) or IL-1L plus the indicated concentrations of xanthine oxi-
dase and 50 WM hypoxanthine, or DMNQ for 24 h. NO32 concen-
trations were determined in the supernatant by the Griess reaction.
Values were corrected for total protein content per 100-mm dish.
Data are means þ S.D. and were obtained from three independent
experiments.
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iNOS mRNA content in MC in a concentration dependent
manner up to 23-fold and 3.1-fold for HXXO and DMNQ,
respectively (Fig. 3). This indicates that coinduction of cyto-
kine-driven iNOS expression by O32 occurs most likely at the
transcriptional level.
We have recently cloned genomic DNA fragments that rep-
resent the promoter of the rat iNOS gene [19,25]. Functional
analysis of the iNOS promoter showed that only 600 bp of the
promoter region are required for cytokine- or cAMP-medi-
ated induction of iNOS [16]. Nevertheless, so far there is no
evidence that this promoter region is su⁄cient to mediate all
modulatory e¡ects of cytokines or cAMP-elevating agents on
iNOS expression. Therefore we cloned an additional 14 kb of
the 5P-£anking region of the iNOS gene. To evaluate whether
the observed e¡ects of ROS on IL-1L-mediated iNOS expres-
sion occur on a transcriptional level we transfected two pro-
moter fragments of 1700 bp length, represented by pGL3/2,
and 4500 bp length, represented by pGL3/4, that were fused
to the luciferase gene in MC. Transiently evoked luciferase
activity was then compared in cells treated with IL-1L and
IL-1L plus HXXO for 24 h after transfection. HXXO (5
mU/ml) enhanced transient luciferase activity IL-1L treated
MC transfected with either pGL3/2 or pGL3/4. However,
whereas O32 caused a 10-fold ampli¢cation of luciferase activ-
ity in pGL3/4-transfected MC there was only a 3.3-fold in-
crease in pGL3/2-transfected cells (Fig. 4) indicative for O32 -
sensitive regulatory elements in the far upstream region of the
iNOS promoter.
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Fig. 3. E¡ects of HXXO and DMNQ on cytokine-induced iNOS-
mRNA steady-state levels. Quiescent MC were treated with vehicle
(control), IL-1L (1 nM) or IL-1L plus the indicated concentrations
of xanthine oxidase and 50 WM hypoxanthine, or DMNQ. After 24
h cells were harvested for total RNA preparation. Membranes were
hybridized to a radiolabelled cDNA fragment of pMac-NOS. Equiv-
alent loading of the RNA probes was corrected after rehybridization
of the ¢lter with a probe for L-actin (pEX6). iNOS mRNA levels
were detected, visualized (A) and evaluated (B) by use of the auto-
mated detector system BAS 1500 of Fuji¢lm (Raytest, Strauben-
hardt, Germany). mRNA levels for iNOS were corrected with
mRNA levels for L-actin and expressed as arbitrary units (B).
Fig. 4. Modulation of IL-1L-induced iNOS promotor activity by
HXXO. MC grown in six-well plates were transfected with 2.5 Wg
pGL3/2 or pGL3/4 plasmid DNA and additionally with plasmid
pRL_CMV that contains the gene for Renilla luciferase fused to a
strong constitutive promoter of the Cytomegalus virus (Promega).
After 24-h incubation with the indicated agents, dual luciferase as-
says (using two di¡erent substrates for the di¡erent luciferase en-
zymes) were performed with an automated chemiluminescence detec-
tor (Berthold, Bad Wildbad, Germany). Values for beetle luciferase
were related to values for Renilla luciferase and the promoter activ-
ity expressed as fold induction vs. luciferase activity in vehicle
treated MC. Data are means þ S.D., n = 3.
Fig. 2. Coinduction of IL-1L evoked iNOS protein expression by
O32 generators. Quiescent MC were treated with vehicle (control),
IL-1L (1 nM) or IL-1L plus the indicated concentrations of xanthine
oxidase and 50 WM hypoxanthine (Fig. 2A), or DMNQ (Fig. 2B)
for 24 h. Protein lysates (100 Wg) were subjected to SDS-PAGE and
immunoblotted using the anti-iNOS N-terminal antibody (see Sec-
tion 2). The blots were developed with the ECL-System (Amer-
sham-Buchler) and the intensity of the bands representing iNOS
protein (130 kDa) evaluated by densitometry.
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4. Discussion
The concept of ROS and NO forming the major e¡ectors in
immune-mediated glomerular diseases is based on an increas-
ing number of in vitro and in vivo studies [9,10,28,29]. Bruºne
et al. [30] have established that a balanced and simultaneous
generation of both radicals is non-destructive for MC whereas
the unopposed formation of either O32 or NO induces apop-
tosis or even necrotic cell death [11,15,31]. Moreover, ROS
and NO also exert their e¡ects by regulating the expression of
other in£ammatory mediators involved in glomerular disease
[20,32^35], possibly by in£uencing the activity of transcription
factors [36,37]. In line with these reports we have observed a
dramatic ampli¢cation of IL-1L-mediated activity of the iNOS
promoter by O32 .
Recently, Jaimes et al. [38] reported that H2O2, the ¢rst
ROS product generated in the O32 metabolizing pathway in-
hibits IL-1L-mediated NO production in MC via a posttran-
scriptional mechanism. At ¢rst glance this is in contrast with
our observations, but Jaimes and colleagues also observed an
increase of iNOS mRNA steady-state levels by H2O2 in MC
challenged with IL-1L. In fact, the high transcriptional activity
of the iNOS gene (Figs. 3 and 4) is in contrast with the
relatively low values concerning the iNOS protein content
and activity (Figs. 1 and 2). This suggests that mechanisms
are operative that counteract at the posttranscriptional level
the high transcriptional activity induced by O32 donors an
assumption that is currently under investigation in our labo-
ratory. The regulation of iNOS gene expression by O32 or
more generally speaking by oxidants or the redox state of
the cell, possibly involving redox-regulated transcription fac-
tors like NF-UB or AP-1 [14], is of prime importance and may
provide new therapeutic approaches for the treatment of in-
£ammatory diseases.
In summary, we conclude from our data that O32 generation
in the in£amed glomerulus may augment severity of glomer-
ular diseases at least in part by up-regulation of iNOS expres-
sion. The crosstalk between O32 and NO and their generating
systems as well at its relevance for the in vivo situation has to
be elucidated in further experiments.
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